Study #PA19-0535
Risk and protective factors for long-term hearing loss secondary to cisplatin chemotherapy.
MD Anderson Study Status
Enrolling
Treatment Agent
Description
Long-term hearing loss secondary to cisplatin chemotherapy
Resources and Links
Phone Number: 1-877-MDA-6789
clinicaltrials.gov NCT No: N/A
Information and next steps
Disease:
Study phase:
Not applicable
Physician name:
Marc-Elie Nader
Department:
Head & Neck Surgery
For general questions about clinical trials:
1-877-327-0346
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.